Richard Aranda - Jun 21, 2021 Form 3 Insider Report for Gossamer Bio, Inc. (GOSS)

Role
Chief Medical Officer
Signature
/s/ Jeff Boerneke, Attorney-in-Fact
Stock symbol
GOSS
Transactions as of
Jun 21, 2021
Transactions value $
$0
Form type
3
Date filed
6/22/2021, 08:10 PM
Next filing
Oct 26, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding GOSS Common Stock 205K Jun 21, 2021 Direct F1
holding GOSS Common Stock 2.54K Jun 21, 2021 By family trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding GOSS Stock Option (Right to Buy) Jun 21, 2021 Common Stock 38.7K $10.71 Direct F2
holding GOSS Stock Option (Right to Buy) Jun 21, 2021 Common Stock 45K $22.10 Direct F3
holding GOSS Stock Option (Right to Buy) Jun 21, 2021 Common Stock 13.8K $16.40 Direct F4
holding GOSS Stock Option (Right to Buy) Jun 21, 2021 Common Stock 34.2K $14.55 Direct F5
holding GOSS Stock Option (Right to Buy) Jun 21, 2021 Common Stock 60K $9.79 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 13,838 shares subject to forfeiture, which shares will vest in equal monthly installments as set forth in the restricted stock agreement between the Issuer and Reporting Person so that all of the shares will be released from the forfeiture restriction on November 18, 2021, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Also includes 65,247 restricted stock units, which shares will vest in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date.
F2 24,180 shares subject to the option have vested and are fully exerciseable and 1/48th of the total number of shares subject to the option vest on July 10, 2021 and the last day of each one-month period thereafter through December 10, 2022, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
F3 24,375 shares subject to the option have vested and are fully exerciseable and 1/48th of the total number of shares subject to the option vest on June 25, 2021 and the last day of each one-month period thereafter through March 25, 2023, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
F4 4,869 shares subject to the option have vested and are fully exerciseable and 1/48th of the total number of shares subject to the option vest on June 23, 2021 and the last day of each one-month period thereafter through December 23, 2023, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
F5 11,391 shares subject to the option have vested and are fully exerciseable and 1/48th of the total number of shares subject to the option vest on July 14, 2021 and the last day of each one-month period thereafter through February 14, 2024, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
F6 25% of the total number of shares subject to the option will vest on February 25, 2022 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.